Refusal to File Stalls EpiCept's AML Drug; Another Trial?
By Jennifer Boggs
Tuesday, August 24, 2010
Shares of EpiCept Corp. plunged 38.3 percent Monday after the FDA refused to accept its new drug application for Ceplene (histamine dihydrochloride) in combination with interleukin-2 as a maintenance therapy for acute myeloid leukemia and, instead, recommended an additional pivotal trial. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.